The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Effective treatments of neurodegenerative diseases require drugs to be actively transported
across the blood-brain barrier (BBB). However, nanoparticle drug carriers explored for this …

Drug delivery to the brain is hampered by the presence of the blood-brain barrier, which
excludes most molecules from freely diffusing into the brain, and tightly regulates the active …

Glioblastoma (GBM) is the most common malignant adult brain cancer with no curative
treatment strategy. A significant hurdle in GBM treatment is effective therapeutic delivery to …

Brain drug delivery may be restricted by the blood-brain barrier (BBB), and enhancement by
liposome-based drug delivery strategies has been investigated. As access to the human …

The blood-brain barrier (BBB) is a major obstacle to treating several brain disorders.
Focused ultrasound (FUS) in combination with intravascular microbubbles increases BBB …

The purpose of this study was to quantitatively investigate how conjugation of GSH to
different liposomal formulations influence the brain delivery of methotrexate (MTX) in rats …

The impact of liposomal formulations on the in vivo release and brain delivery of
methotrexate (MTX) was quantitatively assessed in rats. Two PEGylated liposomal MTX …

Due to many adverse effects of conventional chemotherapy, novel methods of targeting
drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for …